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Table 1. Causes of Lung Cancer
Smoking
Secondhand smoke exposure
Indoor radon
Occupational carcinogens, e.g., asbestos, 
arsenic, radon, chloromethyl ether
Outdoor air pollution
? Diet, other occupational factors
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Approximately 30% of all cancers in developed countries are caused 
by smoking and 80-90% of all lung cancers. Currently in the United 
States, approximately 50% of patients diagnosed with lung cancer are 
former smokers or never smokers with the remaining 50% being persis-
tent smokers. 76% of head and neck cancers are attributed to smoking 
and 51% continue to smoke during their therapy. These numbers are 
more difﬁcult to ascertain in more developing countries where the 
epidemic of smoking is in a different, earlier stage. However, there an 
estimated 1 billion smokers in the world today, and the majority are 
in developing countries. Therefore, the tobacco caused cancers, such 
as lung cancer will only continue to be an epidemic unless effective 
cessation programs are immediately instituted. Oncologists are acutely 
aware of the dangers of cigarette smoking and its relationship to car-
cinogenesis, however, they are not sufﬁciently active in helping their 
patients, already diagnosed with lung cancer, to stop them from persis-
tent smoking. In order to maximize clinical outcomes from therapy, it 
is important for the oncologists to work aggressively with their patients 
who are still smoking. It is not “too late”, and it is not too difﬁcult or 
too stressful for their patients to stop smoking. What is striking in the 
literature is the paucity of studies examining concurrent smoking status 
as related to treatment outcomes. It is unclear whether the oncologists 
are closely monitoring their patient’s smoking status or even consid-
ering it as a possible source of co-morbidity. Prospective studies are 
critical to examine the speciﬁc effect of smoking status on lung cancer 
chemotherapy or radiation therapy.
Current expert smoking cessation guidelines recommend two levels of 
intervention: in the primary care or oncologist’s ofﬁce or by a special-
ist in smoking cessation clinics or quitlines. The initial oncology ofﬁce 
visit is the ideal opportunity to explain the importance of cessation and 
to offer advice about stopping smoking.
The cornerstone of a smoking cessation strategy is the routine provision 
of the ‘”’5 A’s” with the use of pharmacotherapy. If there is a Quitline 
or other cessation services available, the ﬁrst 2 A’s with an R (refer to 
cessation services) are the recommend guideline.
The 5 A’s are:
ASK - about smoking status, how soon do they have their ﬁrst cigarette 
in the morning, number of cigarettes per day, how many times have 
they tried quit, what medication or method have they tried before and 
record it in the patient’s chart.
ADVISE - current smokers that if they quit, they will probably have 
an improved outcome from their oncologic therapy and a decrease 
potential for side effects. Personalize the reasons for stopping smoking 
and relate the reasons to their treatment. Have the patient set a quit date 
either for the current day, or within the next few days. Record in the 
patient’s chart their responses and intentions.
ASSESS - the current motivational status of the smoker to stop. Con-
sider a brief questionnaire that would identify the smoking status with 
the clinical intake form. Normally this step includes the assessment 
of whether the patient is ready to quit. However, for a patient with a 
diagnosis of lung cancer, this should be an abbreviated step. Use their 
diagnosis and need for treatment as the perfect teachable moment
ASSIST - smokers motivated to stop smoking by providing advice 
and support AND appropriate pharmacological therapy. Utilize the op-
portunity for referrals to quitlines that have been developed around the 
world. These quitlines provide cessation advice and support, are usu-
ally free and effective. The clinical ofﬁce simply identiﬁes the smoking 
status, reinforces the importance of stopping smoking and then refers 
the patient to the Quitline or cessation services. In some centers, such 
as Memorial Sloan-Kettering Hospital in New York City or the MD 
Anderson Cancer Center in Houston Texas, there are excellent referral 
programs that help patients to stop smoking within the center.
When assisting the patient to stop smoking, pharmacotherapy should be 
recommended to increase the efﬁcacy of the counseling therapy. Bupro-
pion SR 150 mg PO BID or varenicline xxx BID can be recommended 
for cessation therapy. At present, with the increasing information about 
the anti-apoptotic and proliferative effects of nicotine, NRT is not 
recommended for cessation therapy for a patient who has a diagnosis of 
cancer. When considering bupropion, there should be an assessment of 
a history of previous or current seizure or eating disorder, recent or cur-
rent use of MAOIs, severe hepatic cirrhosis, bipolar disorder, or drug 
interactions with theophylline, tricyclics, SSRIs, MAOIs, antipyschot-
ics, beta-blockers, class 1c antiarrhythmics, enzyme inducers, orphen-
adrine, cyclophosphamide. Of course, persistent smoking should also 
be considered with its concomitant drug interactions.
The patient should be urged to participate in the behavioural support 
programs that are offered with either Zyban, Chantix/Champix or Quit-
line/cessation services. These behavioral support programs may also 
be provided by their insurance companies in the USA. Other sources 
of support should be made available either through the oncology clinic, 
various other organizations, for example the American Cancer Society, 
or perhaps most easily through the state or national Quitline. Learn 
if you have one available! Behavioral support is critically important, 
especially for the lung cancer patient who not only just received a 
life-threatening diagnosis, but also must stop one of the most addictive 
substances in our society.
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Table I contrasts the two forms of pharmacotherapy.
Bupropion HCL SR (Zyban) Varenicline (Chantix or Champix)
Available by prescription Available by prescription
Believed to act directly on the pathways in the 
brain responsible for nicotine dependence and 
withdrawal
Partially replaces one form of nicotine delivery 
with a drug that works at the same site of action 
as nicotine (partial nicotine receptor agonist)
Reduces withdrawal symptoms and craving 
for cigarettes
Reduces withdrawal symptoms and craving 
for cigarettes
Start using 1 week before stopping smoking Start using 1 week before stopping smoking
120 tablet course – 1 (150 mg) tablet once a day 
for the ﬁrst 3 days then 1 (150 mg) tablet twice a 
day for 7-9 weeks – can be continued
0.5 mg PO qd for days 1-3; 0.5 mg PO BID for days 
4-7; 1 mg PO BID for 11 weeks; can be continued
‘Non-nicotine’ therapy ‘Non-nicotine’ therapy
ARRANGE - follow-up visit, best timed with the next oncology clinic 
visit, to check on progress and offer further advice and support as nec-
essary. Congratulate and encourage on-going cessation with routine fol-
low-ups. The oncologist and nurses should work to prevent relapse to 
by encouraging active discussion of the potential gained health beneﬁts 
and possible improved responses to therapy.
PATIENTS WHO RELAPSE or UNWILLING TO QUIT
Most smokers make several attempts to stop before ﬁnally succeeding; 
therefore relapse should not be unexpected. If a smoker has experi-
enced severe withdrawal effects or has requested more intensive help, 
consider referral to a specialist smoking cessation clinic. Higher rates 
can often be achieved with these more intensive specialist clinics. Both 
individual and group treatment can be offered by clinics. Refer the 
patient back to the available Quitline or cessation services.
Use the “5R’s” to discuss smoking cessation with patients who are not 
currently motivated to quit:
Relevance - make cessation personally and speciﬁcally relevant to 
patient’s disease or health risk, family or social situation
Risks - discuss with the patient the risks of ongoing smoking, including 
risks of ‘light’ or ﬁltered cigarettes
Rewards - identify the beneﬁts speciﬁcally for the patient, such as 
improved response to therapy, better quality and length of life, save 
money, provide healthier environment for their family
Roadblocks - discuss the potential barriers to quitting smoking, their 
fears of why they might not be successful
Repetition - repeat this motivational intervention with each visit
It is critical for the oncology patient (and their family) to clearly un-
derstand the message that stopping smoking or other tobacco use, is im-
portant to their treatment plan and outcome. This message and response 
should be recorded into the patient record on every visit. Not until the 
healthcare provider adopts this approach will we be able to decrease the 
number of patients who persist with the intake of numerous drugs or 
chemicals multiple times per day that negatively impact on their treat-
ment outcomes - ie, from their smoking.
Below is a sample questionnaire that could be incorporated into 
the intake form for the clinic.
Clinical assessment of smoking status
Name__________________________ Date ___________________
1. Do you smoke now? Yes No (circle one)
2. If you have ever smoked, for how many years did you smoke? 
(circle one)
  1-2 yrs
  5-10 yrs
  >10 yrs
3. If you have quit smoking, how long ago did you quit?
  _________ years
4. If you used to smoke, or still do: how many cigarettes do you 
smoke each day? (circle one)
  <10 cig/day
  10-20 cig/day
  >20 cigs/day
5. When do you have your ﬁrst cigarette of the day? (circle one)
  no particular time
  within 30 minutes of waking up
  after 30 minutes of waking up
6. Did you experience any cravings/withdrawal symptoms? 
(if yes, check all that apply)
  lethargy
  depression
  irritability
  impaired concentration
  restlessness
7. How many times have you tried to quit using tobacco before? 
(circle one)
 none
 1-2 times
 3 or more times
8. What methods to quit have you tried before? 
(Circle all that apply)
  Quit on my own (Cold Turkey)
  Nicotine gum or lozenge
  Nicotine patch
  Nicotine Inhalator
  Nicotine nasal spray
  Zyban (bupropion)
  Champix/Chantix (varenicline)
  Other ___________________
9. Expected challenges to quit attempts (circle all that apply)
  other household smokers
  cravings
  weight gain
  personality changes
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS140
  Other __________________
10. Are you motivated to make quit using tobacco? (circle one)
  yes maybe no
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Tobacco is the single largest preventable cause of death in the world, 
which killed an estimated 5.4 million people in 2006. Trends indi-
cate that by 2030, 70% of the total deaths will occur in developing 
countries. It is currently responsible for the death of one in ten adults 
worldwide. Half the people that smoke today - that is about 650 million 
people - will eventually be killed by tobacco. The World Health report 
2002 ranked tobacco consumption as the second leading risk factor 
globally, while for industrialized countries, with just over one-ﬁfth of 
the world’s population , tobacco is the leading risk factor, accounting 
for about 12% of all disease and injury burden. 
Overwhelming evidence showed that tobacco use is harmful and ad-
dictive. All forms of tobacco cause many fatal and disabling health 
problems throughout the life cycle.
As the estimated number of attributable deaths increased with one mil-
lion in ten years (1990-2000) the world faced a rapid evolution of the 
tobacco epidemic with the increase of the burden being most marked 
in developing countries. The spread, as well as the reinforcement of the 
epidemics carried out through complex mix of factors that transcend 
national borders. Most of the smoking-related disease burden is still 
found in industrialized countries and the burden of disease attributable 
to tobacco concentrates in countries with a higher prevalence of smok-
ing, countries with a very high number of smokers if only because of 
their demographic size, and or countries with limited capacity to face 
the tobacco epidemic. Globalization of the epidemic restricts the capac-
ity of countries to regulate tobacco through domestic legislation alone 
- making international coordination of policies essential.
The association between tobacco smoking and cancer was demonstrat-
ed by Sir Richard Doll’s in 1950, in his paper that has become a public 
health classic. After a half of a century, the Report of the Surgeon 
General in 2004 stated not only that “cancer is the second leading cause 
of death” but also the fact that cancer “was among the ﬁrst diseases 
causally linked to smoking”. We know that lung cancer is the most fre-
quent cause of cancer death, and cigarette smoking causes most cases. 
Tobacco’s role in increasing the chance of lung cancer is one of the 
most widely known of tobacco’s harmful effects on human health. An 
overwhelming 87% of lung cancer deaths can be attributed to tobacco 
use. For smoking-attributable cancers, the risk generally increases with 
the number of cigarettes smoked and the number of years of smok-
ing, and generally decreases after quitting completely. The risk of 
dying from lung cancer is more than 22 times higher among men who 
smoke cigarettes and about 12 times higher among women who smoke 
cigarettes compared with never smokers. Besides lung cancer, tobacco 
use also causes increased risk for cancer of the mouth, nasal cavities, 
larynx, pharynx, esophagus, stomach, liver, pancreas, kidney, bladder, 
uterine cervix, and myeloid leukemia.
In developed countries, where the tobacco epidemic took hold much 
earlier than in the rest of the world, tobacco-related cardiovascular and 
lung diseases and cancers cause a signiﬁcant proportion of total deaths 
and chronic disability. 
In developing countries tobacco is one of the leading risk factors and its 
importance is growing quickly even in countries where infectious and 
maternal and child problems have traditionally dominated the ranking 
of most frequent diseases. It is urgent to act now at country-level to 
stop the tobacco epidemic. 
The constant challenge for tobacco control in the countries is to “clear 
the smoke” surrounding tobacco issues. And this can be done through 
educating the decision makers and policy leaders on the feasible and 
cost-effective tobacco control measures that will protect public health. 
While the involvement of the decision makers is of major importance 
for tobacco control, the contribution of physicians, as well as all health 
professional, is critical as they are the ones in direct communication 
with the patients. They can educate their patients about the personal 
health costs of tobacco use. Some of the tobacco control interventions 
aim to educate the public to “inform” the government that represents 
it about the public health costs. Another challenge faced by tobacco 
control is to anticipate and counter the opposition. The tobacco industry 
is a prime example of how global business operations can be promot-
ing cigarette consumption while at the same time distorting public 
perceptions of the risks involved. Because cancer is a concern for many 
people, and tobacco has been inextricably linked to the use of tobacco, 
many organizations in the world are now committed to tobacco control. 
Besides public health campaigning groups, health authorities, as well 
as private companies (i.e. pharmaceutical companies) aim to inﬂuence 
policies to control risks.
Experience has shown that there are many cost-effective tobacco con-
trol policies and measures that can be used in different settings and that 
can have a signiﬁcant impact on tobacco consumption. 
The most cost-effective strategies are population-wide public poli-
cies, like tobacco tax and price increases, complete bans on direct and 
indirect tobacco advertising, establishment of smoke-free environments 
in all public and workplaces, and large clear pictorial health messages 
on tobacco packaging. All these measures are included as provisions of 
the ﬁrst international public health treaty, which is the WHO Frame-
work Convention on Tobacco Control (WHO FCTC). This treaty is 
the global response to the global impact of tobacco and the lack of 
comprehensive and sustainable tobacco control programs. Through the 
WHO FCTC, governments recognized the danger for the global public 
health as well as the need for more stringent tobacco control uniformly 
recognized - including the above-mentioned evidence-based measures: 
increased taxation, bans on advertising, and the introduction or expan-
sion of smoke-free environments and cessation programmes.
WHO FCTC entered into force on 27 February 2005, and it repre-
sents a breath of fresh air to re-invigorate tobacco control efforts that 
establishes tobacco control as a priority on the public health agenda, 
provides an evidence-based tool for adoption of sound tobacco control 
measures and also introduces a mechanism for ﬁrm country commit-
ment and accountability. The level of global support and commitment 
has been phenomenal, the Treaty quickly became one of the most 
widely embraced UN Treaties, and has garnered currently 146 contract-
ing parties. 
